MX2019005125A - Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular. - Google Patents
Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular.Info
- Publication number
- MX2019005125A MX2019005125A MX2019005125A MX2019005125A MX2019005125A MX 2019005125 A MX2019005125 A MX 2019005125A MX 2019005125 A MX2019005125 A MX 2019005125A MX 2019005125 A MX2019005125 A MX 2019005125A MX 2019005125 A MX2019005125 A MX 2019005125A
- Authority
- MX
- Mexico
- Prior art keywords
- isoform
- immunologically
- agent
- antibody
- cell surface
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70589—CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196860 | 2016-11-02 | ||
| EP16196858 | 2016-11-02 | ||
| PCT/EP2017/059799 WO2017186718A1 (en) | 2016-04-25 | 2017-04-25 | Allele editing and applications thereof |
| EP17197820 | 2017-10-23 | ||
| PCT/EP2017/077826 WO2018083071A1 (en) | 2016-11-02 | 2017-10-30 | Immunologically discernible cell surface variants for use in cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005125A true MX2019005125A (es) | 2019-08-29 |
Family
ID=62075802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005125A MX2019005125A (es) | 2016-11-02 | 2017-10-30 | Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular. |
Country Status (21)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201708257UA (en) | 2015-04-06 | 2017-11-29 | Subdomain Llc | De novo binding domain containing polypeptides and uses thereof |
| IL258491B2 (en) | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| EP3448995A1 (en) * | 2016-04-25 | 2019-03-06 | Universität Basel | Allele editing and applications thereof |
| ES3024357T3 (en) * | 2017-02-17 | 2025-06-04 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
| KR102709603B1 (ko) | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| AU2018368431B2 (en) | 2017-11-14 | 2024-03-21 | Arcellx, Inc. | Multifunctional immune cell therapies |
| SI3710067T1 (sl) | 2017-11-14 | 2026-01-30 | Arcellx, Inc. | Polipeptidi, ki vsebujejo D-domeno, in njihova uporaba |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| CN112654710A (zh) | 2018-05-16 | 2021-04-13 | 辛瑟高公司 | 用于指导rna设计和使用的方法和系统 |
| ES3061216T3 (en) | 2018-06-29 | 2026-03-31 | Hope City | Cd6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| US20220160870A1 (en) * | 2018-08-28 | 2022-05-26 | Roche Innovation Center Copenhagen A/S | Neoantigen engineering using splice modulating compounds |
| EP3908372A1 (en) * | 2019-01-13 | 2021-11-17 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Antibodies specific to human nectin-2 |
| KR102689877B1 (ko) * | 2019-11-28 | 2024-08-01 | 주식회사 센트릭스바이오 | CD300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 |
| US12616734B2 (en) | 2019-11-28 | 2026-05-05 | CentricsBio, Inc. | Chimeric antigen receptor specifically binding to cd 300C antigen or receptor thereof |
| US20230076643A1 (en) * | 2019-12-30 | 2023-03-09 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
| KR102347797B1 (ko) * | 2020-03-03 | 2022-01-07 | 한국과학기술원 | 대식세포 세포 표면 항원 및 이의 다양한 용도 |
| EP4126243A4 (en) * | 2020-03-27 | 2024-06-12 | The Trustees of Indiana University | Immunotherapeutic targets in multiple myeloma and methods for their identification |
| AU2021413252A1 (en) * | 2020-12-31 | 2023-06-08 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
| WO2022150831A1 (en) * | 2021-01-07 | 2022-07-14 | Innovative Cellular Therapeutics Holdings, Ltd. | Car cells and polyspecific binding molecules for treating solid tumor |
| CN112852875B (zh) * | 2021-02-26 | 2022-10-21 | 福建省立医院 | 示踪肿瘤T淋巴细胞浸润的CD3e转基因小鼠模型的构建方法 |
| CN113125754A (zh) * | 2021-04-16 | 2021-07-16 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的23抗体试剂盒及应用 |
| CN113125755A (zh) * | 2021-04-16 | 2021-07-16 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的9抗体试剂盒及应用 |
| CN113109575A (zh) * | 2021-04-16 | 2021-07-13 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的40抗体试剂盒及应用 |
| CN113125718A (zh) * | 2021-04-16 | 2021-07-16 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的45抗体试剂盒及应用 |
| CN113125733A (zh) * | 2021-04-16 | 2021-07-16 | 浙江普罗亭健康科技有限公司 | 一种用于监测人体免疫状态的42抗体试剂盒及应用 |
| WO2022246764A1 (zh) * | 2021-05-27 | 2022-12-01 | 中科蓝华(广州)生物医药技术有限公司 | 一种分析cd303+树突状细胞亚群表型和功能的方法及试剂盒 |
| WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| EP4381062A1 (en) | 2021-08-02 | 2024-06-12 | Vor Biopharma Inc. | Compositions and methods for gene modification |
| EP4380693A1 (en) | 2021-08-06 | 2024-06-12 | Universität Basel | Discernible cell surface protein variants for use in cell therapy |
| IL313568A (en) | 2021-12-16 | 2024-08-01 | Universit?T Basel | Distinct cell membrane protein variants of CD117 for use in cellular therapy |
| CA3240875A1 (en) | 2021-12-23 | 2023-06-29 | Stefanie Urlinger | Discernible cell surface protein variants of cd45 for use in cell therapy |
| CN114292830B (zh) * | 2021-12-31 | 2024-05-03 | 复旦大学 | 蛋白SaCas9的抗原表位及其在基因编辑中的应用 |
| WO2024015925A2 (en) * | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| EP4611807A4 (en) * | 2022-11-04 | 2026-07-29 | Univ Leland Stanford Junior | REBALANCING OF THE IMMUNE SYSTEM BY DEPLOYMENT OF HEMATOPOIETIC STEM CELLS ORIENTED TO MYELOID PRODUCTION |
| CN116153401B (zh) * | 2023-01-07 | 2024-01-05 | 杭州链康医学检验实验室有限公司 | 基于pdx的单细胞转录组数据分析方法、系统、设备和介质 |
| JP2026516593A (ja) | 2023-04-03 | 2026-05-26 | ウニバズィテート バーゼル | 細胞治療に使用するためのcd33の識別可能な表面タンパク質変異体 |
| EP4753751A1 (en) | 2023-08-04 | 2026-06-10 | Cimeio Therapeutics AG | Discernible cell surface protein variants of cd52 for use in cell therapy |
| WO2025132801A1 (en) | 2023-12-19 | 2025-06-26 | Cimeio Therapeutics Ag | Discernible protein variants of bcl-2 for use in cell therapy |
| CN120738344A (zh) * | 2025-08-26 | 2025-10-03 | 北京康美天鸿生物科技有限公司 | 检测地中海贫血基因突变的引物组及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002240745A1 (en) * | 2001-03-07 | 2002-09-19 | Andre Schuh | Diagnosis and treatment of blood disorders |
| EP1674479A1 (en) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
| WO2007087453A2 (en) * | 2006-01-27 | 2007-08-02 | Cellerant Therapeutics, Inc. | Compositions and methods for treating haematological proliferative disorders |
| EP3255061B1 (en) * | 2006-11-03 | 2021-06-16 | The Board of Trustees of the Leland Stanford Junior University | Selective immunodepletion of endogenous stem cell niche for engraftment |
| US8697846B2 (en) * | 2007-08-15 | 2014-04-15 | Emory University | Methods of making monoclonal antibodies using fusion-peptide epitope adoptive transfer (F-PEAT) technology |
| JP5688734B2 (ja) * | 2008-12-12 | 2015-03-25 | 国立大学法人 東京大学 | 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤 |
| DK3363902T3 (da) * | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| CN111363047A (zh) * | 2013-03-12 | 2020-07-03 | 分子模板公司 | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 |
| EP3569253A1 (en) * | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| KR20160020554A (ko) * | 2013-06-17 | 2016-02-23 | 슈 생-쥐스땡 | 척추측만 개체의 세포에서 gipcr 신호전달을 증가시키는 방법 |
| WO2016014837A1 (en) * | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Gene editing for hiv gene therapy |
| US10201606B2 (en) * | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| HK1256681A1 (zh) * | 2015-04-06 | 2019-10-04 | President And Fellows Of Harvard College | 用於非清髓性预处理的组合物和方法 |
| EP3370741B1 (en) * | 2015-11-04 | 2025-10-08 | The Trustees of the University of Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
| JP2019508037A (ja) * | 2016-02-16 | 2019-03-28 | イェール ユニバーシティーYale Universit | 標的化遺伝子編集を増強するための組成物およびその使用方法 |
| IL313038A (en) * | 2016-03-14 | 2024-07-01 | Editas Medicine Inc | Crispr/cas-related methods and compositions for treating beta hemoglobinopathies |
| EP3448995A1 (en) * | 2016-04-25 | 2019-03-06 | Universität Basel | Allele editing and applications thereof |
-
2017
- 2017-10-30 US US16/346,185 patent/US20190365806A1/en active Pending
- 2017-10-30 DK DK17797585.1T patent/DK3535392T3/da active
- 2017-10-30 LT LTEPPCT/EP2017/077826T patent/LT3535392T/lt unknown
- 2017-10-30 IL IL266362A patent/IL266362B2/en unknown
- 2017-10-30 EP EP17797585.1A patent/EP3535392B1/en active Active
- 2017-10-30 KR KR1020247009264A patent/KR20240043810A/ko active Pending
- 2017-10-30 CN CN201780067985.1A patent/CN110191948A/zh active Pending
- 2017-10-30 PL PL17797585.1T patent/PL3535392T3/pl unknown
- 2017-10-30 WO PCT/EP2017/077826 patent/WO2018083071A1/en not_active Ceased
- 2017-10-30 ES ES17797585T patent/ES2977969T3/es active Active
- 2017-10-30 SI SI201731518T patent/SI3535392T1/sl unknown
- 2017-10-30 EP EP24155910.3A patent/EP4360639A3/en active Pending
- 2017-10-30 HU HUE17797585A patent/HUE067685T2/hu unknown
- 2017-10-30 FI FIEP17797585.1T patent/FI3535392T3/fi active
- 2017-10-30 AU AU2017355218A patent/AU2017355218B2/en active Active
- 2017-10-30 CA CA3041582A patent/CA3041582A1/en active Pending
- 2017-10-30 MX MX2019005125A patent/MX2019005125A/es unknown
- 2017-10-30 KR KR1020197015826A patent/KR20190072639A/ko not_active Ceased
- 2017-10-30 JP JP2019521099A patent/JP7305539B2/ja active Active
- 2017-10-30 BR BR112019008975-6A patent/BR112019008975A2/pt active IP Right Grant
- 2017-10-30 HR HRP20240842TT patent/HRP20240842T1/hr unknown
- 2017-10-30 SG SG11201903454VA patent/SG11201903454VA/en unknown
-
2019
- 2019-04-16 ZA ZA2019/02426A patent/ZA201902426B/en unknown
-
2023
- 2023-06-28 JP JP2023105962A patent/JP7676472B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201902426B (en) | 2020-10-28 |
| AU2017355218A1 (en) | 2019-05-02 |
| WO2018083071A1 (en) | 2018-05-11 |
| EP4360639A3 (en) | 2024-07-17 |
| DK3535392T3 (da) | 2024-04-22 |
| ES2977969T3 (es) | 2024-09-03 |
| PL3535392T3 (pl) | 2024-07-29 |
| CA3041582A1 (en) | 2018-05-11 |
| SI3535392T1 (sl) | 2024-07-31 |
| EP3535392B1 (en) | 2024-03-27 |
| CN110191948A (zh) | 2019-08-30 |
| IL266362B1 (en) | 2024-03-01 |
| FI3535392T3 (fi) | 2024-05-23 |
| EP4360639A2 (en) | 2024-05-01 |
| KR20240043810A (ko) | 2024-04-03 |
| EP3535392A1 (en) | 2019-09-11 |
| HRP20240842T1 (hr) | 2024-10-11 |
| JP2019533450A (ja) | 2019-11-21 |
| HUE067685T2 (hu) | 2024-11-28 |
| JP7305539B2 (ja) | 2023-07-10 |
| IL266362A (en) | 2019-06-30 |
| JP7676472B2 (ja) | 2025-05-14 |
| KR20190072639A (ko) | 2019-06-25 |
| RU2019116783A (ru) | 2020-12-03 |
| US20190365806A1 (en) | 2019-12-05 |
| SG11201903454VA (en) | 2019-05-30 |
| JP2023126852A (ja) | 2023-09-12 |
| LT3535392T (lt) | 2024-04-25 |
| IL266362B2 (en) | 2024-07-01 |
| RU2019116783A3 (cg-RX-API-DMAC7.html) | 2021-03-05 |
| BR112019008975A2 (pt) | 2019-07-09 |
| AU2017355218B2 (en) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4360639A3 (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| ZA202210065B (en) | Interleukin-21 muteins and methods of treatment | |
| SA522431672B1 (ar) | Cd3 أجسام مضادة للارتباط بـ | |
| MX2024005027A (es) | Anticuerpos de union a cd3. | |
| JP2017538669A5 (cg-RX-API-DMAC7.html) | ||
| EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| EP4342541A3 (en) | Antibody fc variants for increased blood half-life | |
| WO2021181233A3 (en) | Cd80-fc fusion protein and uses thereof | |
| NZ591137A (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
| BRPI0806185A2 (pt) | anticorpo neutralizador de alta potência, fragmento de um anticorpo, molécula de ácido nucléico, vetor, célula, clone de célula b imortalizado, epìtopo, polipeptìdio imunogênico, método para produção de anticorpos, composição farmacêutica, uso de um primeiro anticorpo ou fragmento, composição ou uso, método para tratamento de um sujeito, kit para diagnóstico de infecção por hcmv, método para preparação de uma célula recombinante, método para produção de anticorpos, método de detecção de polipeptìdios e epìtopo que se liga especificamente a um anticorpo | |
| TW200612986A (en) | Human anti-kir antibodies | |
| IL240695B2 (en) | Nme inhibitors and methods of using nme inhibitors | |
| WO2019112978A3 (en) | Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof | |
| MX2025001934A (es) | UN ANTICUERPO HUMANIZADO QUE TIENE ESPECIFICIDAD DE UNIÓN PARA LA INTEGRINA A4ß7 HUMANA PARA USARSE EN LA PREVENCIÓN O REDUCCIÓN DE LA APARICIÓN DE GVHD AGUDA EN UN PACIENTE HUMANO QUE TIENE ALL O AML Y QUE SE SOMETE A ALLO-HSCT | |
| MX2017013177A (es) | Anticuerpo anti-vegfr2 humano para terapia del cancer anti-angiogenica y dirigida. | |
| Alshoubaki et al. | A superior extracellular matrix binding motif to enhance the regenerative activity and safety of therapeutic proteins | |
| BR112018015826A2 (pt) | anticorpos monoclonais específicos egfl6 e métodos de seu uso | |
| WO2020081579A8 (en) | Monoclonal antibodies against human dickkopf3 and uses thereof | |
| WO2019055776A3 (en) | Compositions and methods for treatment of diseases involving cxcl1 function | |
| WO2019066617A3 (ko) | 항 c-met 항체 및 이의 용도 | |
| WO2019066620A3 (ko) | 항 c-met 항체 및 이의 용도 | |
| BR112023025596A2 (pt) | Anticorpo anti-masp-2 e uso do mesmo | |
| EA201992860A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл), мелкоклеточного рака легких (мрл) и других видов рака | |
| WO2020099674A3 (en) | Novel c-met and tmx2 antibodies | |
| NO20091239L (no) | Konjugater av disorazoler og deres derivater med celle bindingsmolekyler, nye disorazol derivater, fremgangsmate for fremstilling og anvendelse derav |